Effect of Cyanobacteria Patients With Chronic Hepatitis B Surface Antigen Quantitative Concentration
|ClinicalTrials.gov Identifier: NCT02953600|
Recruitment Status : Recruiting
First Posted : November 3, 2016
Last Update Posted : November 11, 2016
|Condition or disease||Intervention/treatment|
|HBV Carrier||Dietary Supplement: Standard Dose Spirulina Platensis Other: Zero Spirulina Platensis Dietary Supplement: Double Dose Spirulina Platensis|
Hepatocellular carcinoma (HCC) is a very severe disease in Taiwan caused 7,000 deaths per year, and majorly about 70% is caused by the chronic hepatitis B virus infection. A repeat, long-term, and severe chronic hepatitis would be more possible progressed into liver cirrhosis and HCC. As previous records, there might be 2% of chronic HBV patient would progress to liver cirrhosis, and 5% of the liver cirrhosis's patients would develop to HCC. In some cases, the HBV patient also might directly develop to HCC without liver cirrhosis phase.
Spirulina platensis is a kind of ancient livings for a 3.5 billions years, and had been recognized as a kind of space food by National Aeronautics and Space Administration(USA) because of containing numerous nutrients, especially vitamin B and beta-carotene. Beta-carotene would convert into vitamin A and help keep health vision, skin, and mucosa. With a rich source of vitamins B, especial B12 which is almost only in meals (animal livers), 1.2 grams of Spirulina platensis daily uptake would be sufficient for a human daily need, and also be a very good source for vegetarians. The investigators add the B12 test in this trial as a secondary endpoint to help monitor the absorption rates of the Spirulina platensis in human. Otherwise, the plant pigments in Spirulina platensis would also have many bioactivities on human healthy. Among these bio-activities of Spirulina platensis would contain anti-virus, anti-cancer, immune modulation, anti-inflammation, anti-oxidant, improve liver abnormality, and liver cirrhosis abilities. As previous small scale of clinical trial results in HBV patients provided by Far East Bio-Tec Company, lamivudine combined with oral Spirulina platensis would also improve the sero-conversion rates of HBeAg.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||72 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effect of Cyanobacteria Patients With Chronic Hepatitis B Surface Antigen Quantitative Concentration|
|Study Start Date :||November 2016|
|Estimated Primary Completion Date :||June 2017|
|Estimated Study Completion Date :||August 2017|
Experimental: Standard Dose Spirulina Platensis
Spirulina platensis pill/500mg, 3 pills before each meal /6 pills per day
Dietary Supplement: Standard Dose Spirulina Platensis
As previous small scale of clinical trial results in HBV patients provided by Far East Bio-Tec Company, lamivudine combined with oral Spirulina platensis would also improve the sero-conversion rates of HBeAg.
Active Comparator: Zero Spirulina Platensis
Spirulina platensis pill/500mg, 6 pills before each meal /12 pills per day
Dietary Supplement: Double Dose Spirulina Platensis
As previous small scale of clinical trial results in HBV patients provided by Far East Bio-Tec Company, lamivudine combined with oral Spirulina platensis would also improve the sero-conversion rates of HBeAg. Hence, the investigators would like to see if the investigators could improve sero-conversion rates much faster by taking double dose of Spirulina platensis.
Active Comparator: Double Dose Spirulina Platensis
same as usual, non pill taken
Other: Zero Spirulina Platensis
the zero pill-taken group is a comparison for two other groups.
- HBsAg(quantitative) [ Time Frame: treatment continues for 6 months and checks if HBsAg(quantitative) goes down or remain at the same. ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02953600
|Contact: Ming Shun Wu, Dr||886229307930 ext firstname.lastname@example.org|
|Contact: Shu-Ching Chung +886229307930 ext 7923 email@example.com|
|Study Director:||Ming Shun Wu, Dr||WanFangHospital|